Design, synthesis and biological evaluation of novel thiosemicarbazones as cruzipain inhibitors

Eur J Med Chem. 2023 Jun 5:254:115345. doi: 10.1016/j.ejmech.2023.115345. Epub 2023 Apr 7.

Abstract

Based on the activity of 23 TSCs on CZ taken from the literature, we have developed a QSAR model for predicting the activity of TSCs. New TSCs were designed and then tested against CZP, resulting in inhibitors with IC50 values in the nanomolar range. The modelling of the corresponding TSC-CZ complexes by molecular docking and QM/QM ONIOM refinement indicates a binding mode compatible with what was expected for active TSCs, according to a geometry-based theoretical model previously developed by our research group. Kinetic experiments on CZP suggest that the new TSCs act by a mechanism that involves the formation of a reversible covalent adduct with slow association and dissociation kinetics. These results demonstrate the strong inhibitory effect of the new TSCs and the benefit of the combined use of QSAR and molecular modelling techniques in the design of new and potent CZ/CZP inhibitors.

Keywords: Chagas disease; Cruzipain inhibitors; Drug design; QSAR; Thiosemicarbazones.

MeSH terms

  • Cysteine Endopeptidases
  • Molecular Docking Simulation
  • Protozoan Proteins
  • Thiosemicarbazones* / chemistry

Substances

  • Thiosemicarbazones
  • cruzipain
  • Cysteine Endopeptidases
  • Protozoan Proteins